BioBusiness

Catalent’s acquisition of Paragon Bioservices will provide expertise in expanding gene therapy market.

The growing trend of partnerships between small biotech companies and CDMOs makes the need for conducting CMC due diligence increasingly important.

With the spin-off, Alcon will operate as a standalone company, and Novartis will focus on its core innovative medicines.

While it may not be getting easier, biopharma patent protection is at least becoming more predictable.

Promoting patient compliance with drug regimens extends beyond the formulation laboratory.

A $1.7-billion acquisition CDMO Brammer Bio establishes Thermo Fisher Scientific in viral vector manufacturing.

Alcami Biologics formed to meet market demands for biological drug development services.

Richard Francis will step down as CEO of Sandoz, effective March 31, 2019.

Do patients get what they pay for when they demand cheaper drugs?

The $21.4-billion acquisition will create stand-alone business within Danaher’s life-sciences portfolio.

C-Bridge Capital will form a new biopharmaceutical company, AffaMed Therapeutics, which will collaborate with Samsung Bioepis to accelerate clinical development and registration of Samsung Bioepis’ next-generation biosimilars in China.

Radha Iyer, vice-president and head of Quality and Scientific Affairs, Global Developed Markets, Dr. Reddy’s Laboratories, discusses new initiatives at the company.

Biosimilars, pricing strategies, and technology investments will influence growth in spending on drugs.

CDMO leader Marc Funk will succeed Ridinger as CEO of Lonza.

The US and pharmerging markets will drive growth in drug spending; number of approvals to increase.

Company to focus on innovation, growth, and productivity with creation of new units.

Orphan and cancer drugs continue to lead, but treatments for many common diseases were also approved in 2018.

Drug pricing and reimbursement concerns will continue to hinder industry growth in 2019, according to data and analytics company GlobalData.

Merger cites combined strengths in oncology, immunology and inflammation, and cardiovascular disease.

Pricing pressures, investment volatility, and government disfunction greet Biopharma in 2019.

Compensation and professional challenges are key pieces to solving the biopharma employee satisfaction puzzle.

Bio/pharma companies are successfully launching novel therapies; however, the industry still needs to work on manufacturing innovation.

The proposed $12.7-billion deal includes the spinoff of GSK and Pfizer consumer brands to a new UK-listed company.

More-and earlier-interaction between R&D and payers will be essential if innovative therapies are to become more accessible for patients, and more profitable for manufacturers, said panelists at the 2018 Galien Foundation Forum.

Survey results and record attendance may show positive signs for established and emerging biopharma regions.